Manufacturing and Establishment of the 2nd National Standard for Varicella Vaccine
2010
Kim, Y.H., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Kim, D.K., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Sohn, Y.W., Korea Food and Drug Administration, Seoul, Republic of Korea | Han, E.R., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Kim, S.H., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Lim, J.M., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Won, Y.J., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Yoon, H.S., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Jo, M.H., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Kim, K.S., National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea | Kim, J.O., National Center for Lot Release, National Institute of Food and Drug Safety Evaluation, Seoul, Republic of Korea
Biological products, such as live varicella vaccine, are composed of biological substances derived from biological organisms. It is very difficult to identify these biologics' characteristics by analysis of simple physical and chemical methods alone. So the reference material is essential in order to evaluate the quality of bilogics. The 1'st national standard for varicella live vaccine was manufactured, established in 2002 and 2003, and have been used for the manufacturer's quality control and national lot release since then. As the lack of its availability and the decrease of its stability, this study was initiated by National Institute of Food and Drug Safety Evaluation (NiFDS) in 2008 to manufacture and establish the 2nd national standard for varicella live vaccine. The candidate material was manufactured from one of domestic manufacterers and the joint research of the NiFDS and manufacturers of varicella live vaccine was conducted to estimate of the reliable virus content. In the collaborative study, 3 laboratories including NiFDS performed the virus content test more than 7 times and all assay results were statistically analyzed. The mean coefficient of variation (CV) was 1.24%, and the geometric mean titre (GMT) variation range of each laboratory was low. On the basis of the results of this study, the candidate material of 2nd national standard for varicella live vaccine was assigned a potency of 4.26 log10 pfu/0.5 mL, when reconstituted in 0.7 mL.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Korea Agricultural Science Digital Library